Latest news with #MatthewBiegler
Business Insider
15-05-2025
- Business
- Business Insider
Oppenheimer Sticks to Its Buy Rating for Acrivon Therapeutics, Inc. (ACRV)
Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report) yesterday and set a price target of $9.00. The company's shares closed yesterday at $1.14. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Biegler is an analyst with an average return of -16.2% and a 27.06% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Regeneron, and IDEAYA Biosciences. Acrivon Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $11.43. ACRV market cap is currently $37.63M and has a P/E ratio of -0.46. Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACRV in relation to earlier this year.
Yahoo
27-01-2025
- Business
- Yahoo
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. Oppenheimer 35th Annual Healthcare Life Sciences ConferenceTuesday, February 11th, 2025 at 1:20 PM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Matthew Biegler, Executive Director and Senior Analyst Citi's 2025 Virtual Oncology Leadership SummitWednesday, February 19th, 2025 at 12:00 PM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst A live audio webcast of the conference event, as permitted by the conference host, will be available under the "Investors/Events" section of the IDEAYA website at and/or through the conference host. A replay of the webcast will be accessible for 30 days following the live event. About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 20, 2024. Investor and Media ContactIDEAYA BiosciencesAndres Ruiz BrisenoSenior Vice President, Head of Finance and Investor Relationsinvestor@ View original content to download multimedia: SOURCE IDEAYA Biosciences, Inc. Sign in to access your portfolio
